Upload
ventana-medical-systems-inc
View
430
Download
6
Embed Size (px)
DESCRIPTION
See how companion diagnostics deliver personalized healthcare to those who need it in this informative, compelling infographic.
Citation preview
Companion Diagnostics
to those who need it
of laboratory directors see cost savings as a main benefit of PHC2
40% NEARLY
INCREASE in the number of new cancer drugs entering clinical testing4
50%
1993
-199
8
1999
-200
4
MILLIONannual cost savings for the US health care system if patients with metastatic colorectal cancer receive a genetic test prior to treatment3
740
of pathologists see better response rates & successful outcomes with targeted therapies2
44%
for targeted diagnostics & therapies1
72personalized optionsavailable*
deliver Personalized Healthcare
1. Personalized Medicine Is Playing a Growing Role in Development Pipelines: Tufts Center for the Study of Drug Development. Impact Report, 12 (November/December 2010): 6 http://csdd.tufts.edu/files/uploads/nov-dec_ir_report_summary.pdf
2. Personalised Healthcare Perception Study – Laboratory heads, Summary of key findings 8 April 2014, Ebiquity Research, UK3. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies D. Soulières, W. Greer, Anthony M. Magliocco,
D. Huntsman, S. Young, M.-S. Tsao, S. Kamel-Reid Curr Oncol. 2010 July; 17 (Suppl 1): S31–S40. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901795/4. Clinical success rates for new cancer drugs double while more enter testing. Tufts Center for the Study of Drug Development. Impact Report, 15 (May/
June 2013) 3 http://csdd.tufts.edu/files/uploads/may-jun_2013_ir_summary.pdf
*As of 2011
Path
olog
ists
Labs
Patie
nts
Onc
olog
ists
Soci
ety
© 2014 Ventana Medical Systems, Inc. VENTANA and the VENTANA logo are trademarks of Roche. All other trademarks are the property of their respective owners. Web5258 0514A